Correction: The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection.
[This corrects the article DOI: 10.3389/fimmu.2025.1593153.].
APA
Peng N, Mao LF, et al. (2025). Correction: The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection.. Frontiers in immunology, 16, 1669840. https://doi.org/10.3389/fimmu.2025.1669840
MLA
Peng N, et al.. "Correction: The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection.." Frontiers in immunology, vol. 16, 2025, pp. 1669840.
PMID
40936923
Abstract
[This corrects the article DOI: 10.3389/fimmu.2025.1593153.].
같은 제1저자의 인용 많은 논문 (5)
- Foundations of Artificial Intelligence in Hepatology: What a Clinician Needs to Know.
- HES V2.0: Advancing biomarker-based surveillance for HCC - promise and remaining gaps.
- Hepatitis viruses hijack cellular metabolic pathways to drive replication and disease: Implications for novel therapeutics.
- "Sample-in, result-out" liquid biopsy chip based on immunomagnetic separation and CRISPR detection for multiplex analysis of exosomal microRNAs.
- PARP inhibitors for HRR-deficient metastatic castration-resistant prostate cancer: mechanisms and clinical strategies.